thyroid cancer, nonmedullary, 2
thyroid cancer, nonmedullary, 2
Explore linked clinical trials. Standard reference: MONDO:00085663 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | Adenoma, Oxyphilic, Head and Neck Neoplasms, Hurthle Cell Tumor, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, adenoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, poorly differentiated thyroid gland carcinoma, thyroid Hurthle cell carcinoma, thyroid cancer, nonmedullary, 2, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-09-17 | NCT04544111 | |
| Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, Thyroid Nodule, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid cancer, nonmedullary, 2, thyroid gland disorder, thyroid tumor | Recruiting | Not stated | 2026-05-07 | NCT06730321 | |
| A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thyroid Cancer, Papillary, adenocarcinoma, carcinoma, differentiated thyroid carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, papillary adenocarcinoma, thyroid cancer, nonmedullary, 2, thyroid gland disorder, thyroid gland follicular carcinoma, thyroid tumor | Active, not recruiting | Phase 3 | 2025-09-25 | NCT03690388 |